{"transactions":[{"id":1922145,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":114566,"kind":"person","name":"Nandabalan Krishnan","position":1,"cik":"0001733387","reported_name":"Nandabalan Krishnan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Options","published_at":"2023-04-10T22:20:14.000Z","date":"2023-04-06","kind":"exercise","planned":true,"acquired":false,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options are fully vested and exercisable."}],"balance_after":294000,"derivative":{"exercise_price":0.41,"expiration_date":"2027-08-23","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001104659-23-043694","document":"tm2312272-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465923043694/tm2312272-1_4seq1.xml","form_type":"4"}},{"id":1922144,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":114566,"kind":"person","name":"Nandabalan Krishnan","position":1,"cik":"0001733387","reported_name":"Nandabalan Krishnan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-04-10T22:20:14.000Z","date":"2023-04-06","kind":"sale","planned":true,"acquired":false,"shares":60000,"price":17.32,"value":1039200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 were effected pursuant to a plan that complies with Rule 10b5-1 entered into on August 31, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $17.03 to $17.70. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-23-043694","document":"tm2312272-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465923043694/tm2312272-1_4seq1.xml","form_type":"4"}},{"id":1922143,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":114566,"kind":"person","name":"Nandabalan Krishnan","position":1,"cik":"0001733387","reported_name":"Nandabalan Krishnan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-04-10T22:20:14.000Z","date":"2023-04-06","kind":"exercise","planned":true,"acquired":true,"shares":60000,"price":0.41,"value":24600.0,"ownership":{"direct":true},"balance_after":60000,"source":{"system":"sec-edgar","filing":"0001104659-23-043694","document":"tm2312272-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465923043694/tm2312272-1_4seq1.xml","form_type":"4"}},{"id":2015020,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":114566,"kind":"person","name":"Nandabalan Krishnan","position":1,"cik":"0001733387","reported_name":"Nandabalan Krishnan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-02-14T21:44:48.000Z","date":"2022-11-15","kind":"gift","acquired":true,"shares":291097,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of Parent. The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and indirect stockholder of Parent. On the transaction date, the Reporting Person's spouse receieved by gift shares of Parent representing a 3.4% economic interest in the shares of Issuer that are held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of Parent. The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and indirect stockholder of Parent. On the transaction date, the Reporting Person's spouse receieved by gift shares of Parent representing a 3.4% economic interest in the shares of Issuer that are held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose."}],"balance_after":8546750,"source":{"system":"sec-edgar","filing":"0001104659-23-021791","document":"tm236671-2_5seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465923021791/tm236671-2_5seq1.xml","form_type":"5"}},{"id":2015019,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":114566,"kind":"person","name":"Nandabalan Krishnan","position":1,"cik":"0001733387","reported_name":"Nandabalan Krishnan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-02-14T21:44:48.000Z","date":"2022-11-15","kind":"gift","acquired":false,"shares":291097,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of Parent. The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and stockholder of Parent. On the transaction date, the Reporting Person gifted shares of Parent to his spouse representing an approximate 3.4% economic interest in the shares of Issuer that are held of record by BioXcel LLC. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of Parent. The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and stockholder of Parent. On the transaction date, the Reporting Person gifted shares of Parent to his spouse representing an approximate 3.4% economic interest in the shares of Issuer that are held of record by BioXcel LLC. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose."}],"balance_after":8546750,"source":{"system":"sec-edgar","filing":"0001104659-23-021791","document":"tm236671-2_5seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465923021791/tm236671-2_5seq1.xml","form_type":"5"}},{"id":2015018,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":114566,"kind":"person","name":"Nandabalan Krishnan","position":1,"cik":"0001733387","reported_name":"Nandabalan Krishnan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-02-14T21:44:48.000Z","date":"2022-11-15","kind":"gift","acquired":false,"shares":145549,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. (\"Parent\"). The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and stockholder of Parent. On the transaction date, the Reporting Person gifted shares of Parent representing an approximate 1.7% economic interest in the shares of Issuer that are held of record by BioXcel LLC. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. (\"Parent\"). The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and stockholder of Parent. On the transaction date, the Reporting Person gifted shares of Parent representing an approximate 1.7% economic interest in the shares of Issuer that are held of record by BioXcel LLC. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose."}],"balance_after":8546750,"source":{"system":"sec-edgar","filing":"0001104659-23-021791","document":"tm236671-2_5seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465923021791/tm236671-2_5seq1.xml","form_type":"5"}},{"id":2059806,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":114566,"kind":"person","name":"Nandabalan Krishnan","position":1,"cik":"0001733387","reported_name":"Nandabalan Krishnan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Options","published_at":"2023-01-07T01:00:30.000Z","date":"2023-01-05","kind":"exercise","acquired":false,"shares":25889,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The options are fully vested and exercisable."}],"balance_after":354000,"derivative":{"exercise_price":0.41,"expiration_date":"2027-08-23","underlying":"Common Stock","underlying_shares":25889},"source":{"system":"sec-edgar","filing":"0001104659-23-001945","document":"tm232491-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465923001945/tm232491-1_4seq1.xml","form_type":"4"}},{"id":2059805,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":114566,"kind":"person","name":"Nandabalan Krishnan","position":1,"cik":"0001733387","reported_name":"Nandabalan Krishnan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Options","published_at":"2023-01-07T01:00:30.000Z","date":"2023-01-04","kind":"exercise","acquired":false,"shares":34111,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The options are fully vested and exercisable."}],"balance_after":379889,"derivative":{"exercise_price":0.41,"expiration_date":"2027-08-23","underlying":"Common Stock","underlying_shares":34111},"source":{"system":"sec-edgar","filing":"0001104659-23-001945","document":"tm232491-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465923001945/tm232491-1_4seq1.xml","form_type":"4"}},{"id":2059804,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":114566,"kind":"person","name":"Nandabalan Krishnan","position":1,"cik":"0001733387","reported_name":"Nandabalan Krishnan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-01-07T01:00:30.000Z","date":"2023-01-05","kind":"sale","acquired":false,"shares":800,"price":22.93,"value":18344.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $22.90 to $23.04. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-23-001945","document":"tm232491-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465923001945/tm232491-1_4seq1.xml","form_type":"4"}},{"id":2059803,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":114566,"kind":"person","name":"Nandabalan Krishnan","position":1,"cik":"0001733387","reported_name":"Nandabalan Krishnan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-01-07T01:00:30.000Z","date":"2023-01-05","kind":"sale","acquired":false,"shares":25089,"price":22.32,"value":559986.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $21.90 to $22.89. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."}],"balance_after":800,"source":{"system":"sec-edgar","filing":"0001104659-23-001945","document":"tm232491-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465923001945/tm232491-1_4seq1.xml","form_type":"4"}},{"id":2059802,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":114566,"kind":"person","name":"Nandabalan Krishnan","position":1,"cik":"0001733387","reported_name":"Nandabalan Krishnan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-01-07T01:00:30.000Z","date":"2023-01-05","kind":"exercise","acquired":true,"shares":25889,"price":0.41,"value":10614.49,"ownership":{"direct":true},"balance_after":25889,"source":{"system":"sec-edgar","filing":"0001104659-23-001945","document":"tm232491-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465923001945/tm232491-1_4seq1.xml","form_type":"4"}},{"id":2059801,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":114566,"kind":"person","name":"Nandabalan Krishnan","position":1,"cik":"0001733387","reported_name":"Nandabalan Krishnan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-01-07T01:00:30.000Z","date":"2023-01-04","kind":"sale","acquired":false,"shares":9821,"price":22.21,"value":218124.41,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $22.0367 to $22.42. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-23-001945","document":"tm232491-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465923001945/tm232491-1_4seq1.xml","form_type":"4"}},{"id":2059800,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":114566,"kind":"person","name":"Nandabalan Krishnan","position":1,"cik":"0001733387","reported_name":"Nandabalan Krishnan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-01-07T01:00:30.000Z","date":"2023-01-04","kind":"sale","acquired":false,"shares":24290,"price":21.59,"value":524421.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $21.03 to $22.0263. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."}],"balance_after":9821,"source":{"system":"sec-edgar","filing":"0001104659-23-001945","document":"tm232491-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465923001945/tm232491-1_4seq1.xml","form_type":"4"}},{"id":2059799,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":114566,"kind":"person","name":"Nandabalan Krishnan","position":1,"cik":"0001733387","reported_name":"Nandabalan Krishnan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-01-07T01:00:30.000Z","date":"2023-01-04","kind":"exercise","acquired":true,"shares":34111,"price":0.41,"value":13985.51,"ownership":{"direct":true},"balance_after":34111,"source":{"system":"sec-edgar","filing":"0001104659-23-001945","document":"tm232491-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465923001945/tm232491-1_4seq1.xml","form_type":"4"}},{"id":2117436,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":114566,"kind":"person","name":"Nandabalan Krishnan","position":1,"cik":"0001733387","reported_name":"Nandabalan Krishnan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Options","published_at":"2022-11-15T01:00:35.000Z","date":"2022-11-11","kind":"exercise","acquired":false,"shares":32550,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The options are fully vested and exercisable"}],"balance_after":414000,"derivative":{"exercise_price":0.41,"expiration_date":"2027-08-23","underlying":"Common Stock","underlying_shares":32550},"source":{"system":"sec-edgar","filing":"0001104659-22-118836","document":"tm2230464-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465922118836/tm2230464-1_4seq1.xml","form_type":"4"}},{"id":2117435,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":114566,"kind":"person","name":"Nandabalan Krishnan","position":1,"cik":"0001733387","reported_name":"Nandabalan Krishnan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Options","published_at":"2022-11-15T01:00:35.000Z","date":"2022-11-10","kind":"exercise","acquired":false,"shares":27450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The options are fully vested and exercisable"}],"balance_after":446550,"derivative":{"exercise_price":0.41,"expiration_date":"2027-08-23","underlying":"Common Stock","underlying_shares":27450},"source":{"system":"sec-edgar","filing":"0001104659-22-118836","document":"tm2230464-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465922118836/tm2230464-1_4seq1.xml","form_type":"4"}},{"id":2117434,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":114566,"kind":"person","name":"Nandabalan Krishnan","position":1,"cik":"0001733387","reported_name":"Nandabalan Krishnan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-11-15T01:00:35.000Z","date":"2022-11-11","kind":"sale","acquired":false,"shares":32550,"price":15,"value":488250.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $15.00 to $15.03. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-22-118836","document":"tm2230464-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465922118836/tm2230464-1_4seq1.xml","form_type":"4"}},{"id":2117433,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":114566,"kind":"person","name":"Nandabalan Krishnan","position":1,"cik":"0001733387","reported_name":"Nandabalan Krishnan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-11-15T01:00:35.000Z","date":"2022-11-11","kind":"exercise","acquired":true,"shares":32550,"price":0.41,"value":13345.5,"ownership":{"direct":true},"balance_after":32550,"source":{"system":"sec-edgar","filing":"0001104659-22-118836","document":"tm2230464-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465922118836/tm2230464-1_4seq1.xml","form_type":"4"}},{"id":2117432,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":114566,"kind":"person","name":"Nandabalan Krishnan","position":1,"cik":"0001733387","reported_name":"Nandabalan Krishnan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-11-15T01:00:35.000Z","date":"2022-11-10","kind":"sale","acquired":false,"shares":27450,"price":15,"value":411750.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $15.00 to $15.01. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-22-118836","document":"tm2230464-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465922118836/tm2230464-1_4seq1.xml","form_type":"4"}},{"id":2117431,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":114566,"kind":"person","name":"Nandabalan Krishnan","position":1,"cik":"0001733387","reported_name":"Nandabalan Krishnan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-11-15T01:00:35.000Z","date":"2022-11-10","kind":"exercise","acquired":true,"shares":27450,"price":0.41,"value":11254.5,"ownership":{"direct":true},"balance_after":27450,"source":{"system":"sec-edgar","filing":"0001104659-22-118836","document":"tm2230464-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465922118836/tm2230464-1_4seq1.xml","form_type":"4"}},{"id":2397157,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":114566,"kind":"person","name":"Nandabalan Krishnan","position":1,"cik":"0001733387","reported_name":"Nandabalan Krishnan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-02-14T22:37:37.000Z","date":"2021-04-06","kind":"gift","acquired":false,"shares":102568,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of Parent. The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and stockholder of Parent. On the transaction date, the Reporting Person's spouse gifted shares of Parent representing an approximate 1.3% economic interest in Parent. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of Parent. The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and stockholder of Parent. On the transaction date, the Reporting Person's spouse gifted shares of Parent representing an approximate 1.3% economic interest in Parent. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose."}],"balance_after":8546750,"source":{"system":"sec-edgar","filing":"0001104659-22-023281","document":"tm226624-1_5seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465922023281/tm226624-1_5seq1.xml","form_type":"5"}},{"id":2397156,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":114566,"kind":"person","name":"Nandabalan Krishnan","position":1,"cik":"0001733387","reported_name":"Nandabalan Krishnan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-02-14T22:37:37.000Z","date":"2021-04-06","kind":"gift","acquired":true,"shares":130659,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of Parent. The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and indirect stockholder of Parent. On the transaction date, the Reporting Person's Spouse receieved by gift shares of Parent representing a 1.6% economic interest in Parent from the Reporting Person. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of Parent. The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and indirect stockholder of Parent. On the transaction date, the Reporting Person's Spouse receieved by gift shares of Parent representing a 1.6% economic interest in Parent from the Reporting Person. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose."}],"balance_after":8546750,"source":{"system":"sec-edgar","filing":"0001104659-22-023281","document":"tm226624-1_5seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465922023281/tm226624-1_5seq1.xml","form_type":"5"}},{"id":2397155,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":114566,"kind":"person","name":"Nandabalan Krishnan","position":1,"cik":"0001733387","reported_name":"Nandabalan Krishnan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-02-14T22:37:37.000Z","date":"2021-04-06","kind":"gift","acquired":false,"shares":130659,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of Parent. The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and stockholder of Parent. On the transaction date, the Reporting Person gifted shares of Parent to his spouse representing an approximate 1.6% economic interest in Parent. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of Parent. The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and stockholder of Parent. On the transaction date, the Reporting Person gifted shares of Parent to his spouse representing an approximate 1.6% economic interest in Parent. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose."}],"balance_after":8546750,"source":{"system":"sec-edgar","filing":"0001104659-22-023281","document":"tm226624-1_5seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465922023281/tm226624-1_5seq1.xml","form_type":"5"}},{"id":2397154,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":114566,"kind":"person","name":"Nandabalan Krishnan","position":1,"cik":"0001733387","reported_name":"Nandabalan Krishnan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-02-14T22:37:37.000Z","date":"2021-04-06","kind":"gift","acquired":false,"shares":102568,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. (\"Parent\"). The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and stockholder of Parent. On the transaction date, the Reporting Person gifted shares of Parent representing an approximate 1.3% economic interest in Parent. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. (\"Parent\"). The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and stockholder of Parent. On the transaction date, the Reporting Person gifted shares of Parent representing an approximate 1.3% economic interest in Parent. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose."}],"balance_after":8546750,"source":{"system":"sec-edgar","filing":"0001104659-22-023281","document":"tm226624-1_5seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465922023281/tm226624-1_5seq1.xml","form_type":"5"}},{"id":2651099,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":114566,"kind":"person","name":"Nandabalan Krishnan","position":1,"cik":"0001733387","reported_name":"Nandabalan Krishnan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-29T21:23:06.000Z","date":"2021-06-25","kind":"sale","acquired":false,"shares":473250,"price":30.8283,"value":14589492.975,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On June 25, 2021, BioXcel LLC sold 473,250 shares of common stock of the Issuer as a selling stockholder in an underwritten public secondary offering at a price to the public of $31.70. The reported sale price reflects the price at which BioXcel LLC sold shares to the underwriters after underwriting discounts and commissions."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 25, 2021, BioXcel LLC sold 473,250 shares of common stock of the Issuer as a selling stockholder in an underwritten public secondary offering at a price to the public of $31.70. The reported sale price reflects the price at which BioXcel LLC sold shares to the underwriters after underwriting discounts and commissions."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. (\"Parent\"). The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and stockholder of Parent. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"On June 25, 2021, BioXcel LLC sold 473,250 shares of common stock of the Issuer as a selling stockholder in an underwritten public secondary offering at a price to the public of $31.70. The reported sale price reflects the price at which BioXcel LLC sold shares to the underwriters after underwriting discounts and commissions."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. (\"Parent\"). The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and stockholder of Parent. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Does not include 1,000 shares of the Issuer's common stock inadvertently previously reported as indirectly beneficially owned by The Sunanda Family Trust. Such shares are no longer held by the Reporting Person following the gift disposition of such shares on December 1, 2020."}],"balance_after":8546750,"source":{"system":"sec-edgar","filing":"0001104659-21-086946","document":"tm2119762-8_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465921086946/tm2119762-8_4seq1.xml","form_type":"4"}},{"id":2858161,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":114566,"kind":"person","name":"Nandabalan Krishnan","position":1,"cik":"0001733387","reported_name":"Nandabalan Krishnan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-16T22:28:21.000Z","date":"2020-12-01","kind":"gift","acquired":false,"shares":185150,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of Parent. The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and indirect stockholder of Parent. On the transaction date, the Reporting Person's Spouse gifted shares of Parent representing a 2.05% economic interest in Parent to the Reporting Person. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of Parent. The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and indirect stockholder of Parent. On the transaction date, the Reporting Person's Spouse gifted shares of Parent representing a 2.05% economic interest in Parent to the Reporting Person. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose."}],"balance_after":9020000,"source":{"system":"sec-edgar","filing":"0001104659-21-024416","document":"tm216714-2_5seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465921024416/tm216714-2_5seq1.xml","form_type":"5"}},{"id":2858160,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":114566,"kind":"person","name":"Nandabalan Krishnan","position":1,"cik":"0001733387","reported_name":"Nandabalan Krishnan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-16T22:28:21.000Z","date":"2020-12-01","kind":"gift","acquired":false,"shares":185150,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. (\"Parent\"). The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and stockholder of Parent. On the transaction date, the Reporting Person gifted shares of Parent representing a 2.05% economic interest in Parent to his spouse. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. (\"Parent\"). The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and stockholder of Parent. On the transaction date, the Reporting Person gifted shares of Parent representing a 2.05% economic interest in Parent to his spouse. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose."}],"balance_after":9020000,"source":{"system":"sec-edgar","filing":"0001104659-21-024416","document":"tm216714-2_5seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465921024416/tm216714-2_5seq1.xml","form_type":"5"}},{"id":2858159,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":114566,"kind":"person","name":"Nandabalan Krishnan","position":1,"cik":"0001733387","reported_name":"Nandabalan Krishnan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-16T22:28:21.000Z","date":"2020-07-24","kind":"gift","acquired":false,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-21-024416","document":"tm216714-2_5seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465921024416/tm216714-2_5seq1.xml","form_type":"5"}},{"id":2858157,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":114566,"kind":"person","name":"Nandabalan Krishnan","position":1,"cik":"0001733387","reported_name":"Nandabalan Krishnan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-16T22:26:52.000Z","date":"2020-07-24","kind":"other","acquired":true,"shares":80000,"price":60.76,"value":4860800.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"See footnote (2). These securities were acquired as the result of the distribution of the Issuer's common stock by Parent to the Reporting Person in return for the cancellation of a proportional number of shares owned in Parent owned by the Reporting Person."}],"balance_after":80000,"source":{"system":"sec-edgar","filing":"0001104659-21-024409","document":"tm216714-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465921024409/tm216714-1_4seq1.xml","form_type":"4"}},{"id":2858156,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":114566,"kind":"person","name":"Nandabalan Krishnan","position":1,"cik":"0001733387","reported_name":"Nandabalan Krishnan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-16T22:26:52.000Z","date":"2020-07-24","kind":"other","acquired":false,"shares":160000,"price":60.76,"value":9721600.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. (\"Parent\"). The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and stockholder of Parent. On the transaction date, BioXcel LLC distributed 160,000 shares of the Issuer's common stock to Parent, which in turn distributed 80,000 of such shares to the Reporting Person in return for the cancellation of a proportional number of shares in Parent owned by the Reporting Person. The remaining 80,000 shares of Issuer's common stock were distributed to a different stockholder of Parent in return for the cancellation of a proportional number of shares in Parent held by such other stockholder."},{"field":"kind","element":"transactionCoding","label":"F3","text":"By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. (\"Parent\"). The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and stockholder of Parent. On the transaction date, BioXcel LLC distributed 160,000 shares of the Issuer's common stock to Parent, which in turn distributed 80,000 of such shares to the Reporting Person in return for the cancellation of a proportional number of shares in Parent owned by the Reporting Person. The remaining 80,000 shares of Issuer's common stock were distributed to a different stockholder of Parent in return for the cancellation of a proportional number of shares in Parent held by such other stockholder."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. (\"Parent\"). The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and stockholder of Parent. On the transaction date, BioXcel LLC distributed 160,000 shares of the Issuer's common stock to Parent, which in turn distributed 80,000 of such shares to the Reporting Person in return for the cancellation of a proportional number of shares in Parent owned by the Reporting Person. The remaining 80,000 shares of Issuer's common stock were distributed to a different stockholder of Parent in return for the cancellation of a proportional number of shares in Parent held by such other stockholder."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose."}],"balance_after":9020000,"source":{"system":"sec-edgar","filing":"0001104659-21-024409","document":"tm216714-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465921024409/tm216714-1_4seq1.xml","form_type":"4"}},{"id":2858155,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":114566,"kind":"person","name":"Nandabalan Krishnan","position":1,"cik":"0001733387","reported_name":"Nandabalan Krishnan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-16T22:26:52.000Z","date":"2019-04-01","kind":"gift","acquired":true,"shares":1000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares held by The Sunanda Family Trust."}],"balance_after":1000,"source":{"system":"sec-edgar","filing":"0001104659-21-024409","document":"tm216714-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465921024409/tm216714-1_4seq1.xml","form_type":"4"}},{"id":2858154,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":114566,"kind":"person","name":"Nandabalan Krishnan","position":1,"cik":"0001733387","reported_name":"Nandabalan Krishnan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-16T22:26:52.000Z","date":"2019-04-01","kind":"gift","acquired":false,"shares":1000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-21-024409","document":"tm216714-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465921024409/tm216714-1_4seq1.xml","form_type":"4"}},{"id":3150213,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":114566,"kind":"person","name":"Nandabalan Krishnan","position":1,"cik":"0001733387","reported_name":"Nandabalan Krishnan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-05-13T23:21:31.000Z","date":"2020-02-24","kind":"disposition_to_issuer","acquired":false,"shares":300000,"price":30.08,"value":9024000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The transaction was effected by BioXcel Corporation. Effective April 23, 2020, BioXcel Corporation merged with and into BioXcel LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. (\"Parent\"). The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and shareholder of Parent. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose."}],"balance_after":9180000,"source":{"system":"sec-edgar","filing":"0001104659-20-061009","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465920061009/a4.xml","form_type":"4"}},{"id":3168096,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":114566,"kind":"person","name":"Nandabalan Krishnan","position":1,"cik":"0001733387","reported_name":"Nandabalan Krishnan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-04-28T20:47:56.000Z","date":"2020-01-02","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable as to 25% of the underlying shares on the first anniversary of January 2, 2020 and the remaining 75% of the underlying shares in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer through the relevant vesting dates."}],"balance_after":15000,"derivative":{"exercise_price":13.6,"expiration_date":"2030-01-02","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001104659-20-052445","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465920052445/a4.xml","form_type":"4"}},{"id":3747172,"issuer":{"id":8380,"kind":"organization","name":"BioXcel Therapeutics, Inc."},"owners":[{"id":114566,"kind":"person","name":"Nandabalan Krishnan","position":1,"cik":"0001733387","reported_name":"Nandabalan Krishnan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-11-30T21:17:11.000Z","date":"2018-11-29","kind":"purchase","acquired":true,"shares":1000,"price":4.915,"value":4915.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"By Krishnan Nandabalan and Suganthi Balasubramanian JTWROS"}],"balance_after":1000,"source":{"system":"sec-edgar","filing":"0001104659-18-070832","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465918070832/a4.xml","form_type":"4"}}]}